A practical reference on circadian rhythm: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-03-18 and is reviewed periodically as new material appears.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small molecule | Studied as a REV-ERB agonist |
| Molecular formula | C20H24ClN3O4S | Reported for the neutral compound |
| Appearance | Off-white to pale yellow solid | Typical research-grade material |
| Solubility | Sparingly soluble in water | Soluble in solvents such as DMSO |
| Common synonyms | SR9009; Stenabolic | Stenabolic is an informal alias |
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
La Colombe was founded by Todd Carmichael and JP Iberti in 1994 in the Rittenhouse Square neighborhood of Philadelphia. In 2015, Hamdi Ulukaya, founder of Chobani, purchased a share of the company. Ulukaya bought out private equity firm Goode Partners to gain his stake, and helped the company raise $28.5 million to fund plans for expansion. This purchase made La Colombe one of several small-scale coffee roasters that received large investments or were acquired outright in 2015. In July 2023, Keurig Dr Pepper invested $300 million in La Colombe in exchange for 33% of the company. In December 2023, Chobani fully acquired La Colombe for $900 million. As part of the deal, Keurig Dr Pepper had its 33% equity converted to a minority position in Chobani. Chobani took a $550 million loan to fund the acquisition.
=== North American supply === As the war intensified with German air raids on the UK, Florey and Ethel decided to send their children away to a safer country in July 1940. The United States was not yet at war, and John Fulton, the Sterling Professor of Physiology at Yale University, and his wife Lucia agreed to care for them at their home in New Haven, Connecticut, "for the duration". In April 1941, the Rockefeller Foundation's Warren Weaver met with Florey, and they discussed the difficulty of producing sufficient penicillin to conduct clinical trials. Weaver arranged for the foundation to fund a three-month visit to the United States for Florey and a colleague so they could explore the possibility of the production of penicillin there. Since his aim was to persuade a firm to manufacture penicillin, and Heatley knew the most about penicillin production, Florey chose to take Heatley with him, and did not tell Chain until the morning of their departure. Chain, who saw penicillin as a joint project between himself and Florey, with Heatley as a laboratory technician, was greatly offended. Chain later wrote: "I left the room silently but shattered by the experience of this underhand trick and act of bad faith, the worst so far in my experience of Florey. It spoiled my initially good relations with this man for ever." Florey and Heatley left by air from Lisbon for the United States on 27 June 1941. In New Haven Florey met Fulton and was reunited with his children.
=== Neptunium-239 === Neptunium-239 has 146 neutrons and a half-life of 2.356 days. It is produced via β− decay of the short-lived uranium-239, and undergoes another β− decay to plutonium-239. This is the primary route for making plutonium, as 239U can be made by neutron capture in uranium-238. Uranium-237 and neptunium-239 are regarded as the leading hazardous radioisotopes in the first hour-to-week period following nuclear fallout from a nuclear detonation, with 239Np dominating "the spectrum for several days".
Sources: en.wikipedia.org
Potash is primarily a mixture of potassium salts because plants have little or no sodium content, and the rest of a plant's major mineral content consists of calcium salts of relatively low solubility in water. While potash has been used since ancient times, its composition was not understood. Georg Ernst Stahl obtained experimental evidence that led him to suggest the fundamental difference of sodium and potassium salts in 1702, and Henri Louis Duhamel du Monceau was able to prove this difference in 1736. The exact chemical composition of potassium and sodium compounds, and the status as chemical element of potassium and sodium, was not known then, and thus Antoine Lavoisier did not include the alkali in his list of chemical elements in 1789. For a long time the only significant applications for potash were the production of glass, bleach, soap and gunpowder as potassium nitrate. Potassium soaps from animal fats and vegetable oils were especially prized because they tend to be more water-soluble and of softer texture, and are therefore known as soft soaps. The discovery by Justus Liebig in 1840 that potassium is a necessary element for plants and that most types of soil lack potassium caused a steep rise in demand for potassium salts. Wood-ash from fir trees was initially used as a potassium salt source for fertilizer, but, with the discovery in 1868 of mineral deposits containing potassium chloride near Staßfurt, Germany, the production of potassium-containing fertilizers began at an industrial scale.
This reacts up to 400 fold faster than the original pair with a rate constant of 5.5 ± 0.6 × 105 M−1 s−1. This version is back reactive with the two previous generations of SpyTag/SpyCatcher reagents. SpyTag/SpyCatcher react with specificity even when in the presence of bacterial and mammalian cell environments.
In 1911, Tolkien went on a summer holiday in Switzerland, a trip that he recollected vividly in a 1968 letter, noting that Bilbo's journey across the Misty Mountains ("including the glissade down the slithering stones into the pine woods") is directly based on his adventures as their party of 12 hiked from Interlaken to Lauterbrunnen and on to camp in the moraines beyond Mürren. Fifty-seven years later, Tolkien remembered his regret at leaving the view of the eternal snows of Jungfrau and Silberhorn, "the Silvertine (Celebdil) of my dreams". They went across the Kleine Scheidegg to Grindelwald and on across the Grosse Scheidegg to Meiringen. They continued across the Grimsel Pass, through the upper Valais to Brig and on to the Aletsch glacier and Zermatt. In October of the same year, Tolkien began studying at Exeter College, Oxford. He initially read classics but changed his course in 1913 to English language and literature, graduating in 1915 with first-class honours. Among his tutors at Oxford was Joseph Wright, whose Primer of the Gothic Language had inspired Tolkien as a schoolboy.
The origins of the Cossacks are disputed. According to scientific studies, the Y-chromosomal genetic makeup of Zaporozhian, Don, and Kuban Cossacks forms the southern fragment of the East Slavic population, with minimal or no Caucasian or Asian component in their paternal gene pool. However, the term "Cossack" referred to independent horse-riding communities by the Tatars (qazaq or "free men") who inhabited the Pontic–Caspian steppe, north of the Black Sea near the Dnieper River. By the end of the 15th century, the term was also applied to Slavic peasants who had fled to the devastated regions along the lower Dnieper and Don Rivers, where they established their self-governing, cavalry-based communities. Until at least the 1630s, these Cossack groups remained ethnically and religiously autonomous. There were several major Cossack hosts in the 16th century: near the Dnieper, Don, Volga, and Ural Rivers; the Greben Cossacks in Caucasia; and the Zaporozhian Cossacks, mainly west of the Dnieper. It is unclear when people other than the Brodnici and Berladnici (which had a Romanian origin with large Slavic influences) began to settle in the lower reaches of major rivers such as the Don and the Dnieper after the demise of the Khazars. Their arrival was theorized to have been around the 13th century when the Mongols broke the power of the Cumans, who had assimilated the previous population in that region. It is known that immigrant settlers inherited a lifestyle that long pre-dated their presence, including from that of the Cumans and the Circassian Kassaks.
Sources: en.wikipedia.org
The beta sheet (β-sheet, also β-pleated sheet) is a common motif of the regular protein secondary structure. Beta sheets consist of beta strands (β-strands) connected laterally by at least two or three backbone hydrogen bonds, forming a generally twisted, pleated sheet. A β-strand is a stretch of polypeptide chain typically 3 to 10 amino acids long with backbone in an extended conformation. The supramolecular association of β-sheets has been implicated in the formation of the fibrils and protein aggregates observed in amyloidosis, Alzheimer's disease and other proteinopathies.
In 1963, Sanders and Deborah Shiling Messing, whom he met in college, volunteered for several months on the Israeli kibbutz Sha'ar HaAmakim. They married in 1964 and bought a summer home in Vermont; they had no children and divorced in 1966. His son (and only biological child), Levi Sanders, was born in 1969 to then-girlfriend Susan Campbell Mott. On May 28, 1988, Sanders married Jane O'Meara Driscoll (née Mary Jane O'Meara), who later became president of Burlington College, in Burlington, Vermont. The day after their wedding, the couple visited the Soviet Union as part of an official delegation in his capacity as mayor. They own a row house in Capitol Hill, a house in Burlington's New North End neighborhood, and a lakefront summer home in North Hero. He considers Jane's three children—Dave Driscoll (born 1975), Carina Driscoll (born 1974), and Heather Titus (née Driscoll; 1971)—to be his own. Sanders's elder brother, Larry, lives in England; he was a Green Party county councillor, representing the East Oxford division on Oxfordshire County Council, until he retired from the council in 2013. Larry ran as a Green Party candidate for Oxford West and Abingdon in the 2015 British general election and came in fifth. Bernie Sanders told CNN, "I owe my brother an enormous amount. It was my brother who actually introduced me to a lot of my ideas."
== Contraindications == Like other dihydropyridines, lercanidipine is contraindicated in unstable angina pectoris, uncontrolled cardiac failure, shortly after a myocardial infarction, and in patients with left ventricular outflow tract obstruction. It is also contraindicated during pregnancy and in women who may become pregnant, because data regarding safety for the unborn are lacking, as well as in patients with severe liver and renal impairment. The drug must not be combined with strong inhibitors of the liver enzyme CYP3A4 or with the immunosuppressant drug ciclosporin.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.
No. SR9009 is frequently mislabeled as a SARM in online discussions, but it does not target androgen receptors. Its known mechanism involves REV-ERB nuclear receptors and circadian-metabolic gene regulation.
Human clinical data are very limited. There is no approved human use, and safety and efficacy in people are not established. Most evidence comes from preclinical models, so effects observed in animals may not apply to humans.
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.